Sipai Health Technology Future Growth
Future criteria checks 1/6
Sipai Health Technology is forecast to grow revenue at 16.6% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Consumer Retailing earnings growth | 27.6% |
| Revenue growth rate | 16.6% |
| Future return on equity | 4.4% |
| Analyst coverage | Low |
| Last updated | 05 Aug 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7,185 | N/A | N/A | -34 | 1 |
| 12/31/2025 | 6,293 | N/A | N/A | 149 | 1 |
| 12/31/2024 | 5,468 | N/A | N/A | -92 | 1 |
| 6/30/2024 | 4,638 | -242 | 0 | 11 | N/A |
| 3/31/2024 | 4,675 | -249 | -69 | -61 | N/A |
| 12/31/2023 | 4,712 | -256 | -139 | -133 | N/A |
| 9/30/2023 | 4,691 | -686 | -128 | -123 | N/A |
| 6/30/2023 | 4,670 | -1,117 | -117 | -113 | N/A |
| 3/31/2023 | 4,395 | -1,244 | -155 | -148 | N/A |
| 12/31/2022 | 4,119 | -1,371 | -194 | -182 | N/A |
| 9/30/2022 | 3,966 | -1,474 | -289 | -272 | N/A |
| 6/30/2022 | 3,812 | -1,577 | -385 | -362 | N/A |
| 3/31/2022 | 3,643 | -2,659 | -514 | -492 | N/A |
| 12/31/2021 | 3,474 | -3,740 | -643 | -622 | N/A |
| 12/31/2020 | 2,700 | -1,043 | -207 | -192 | N/A |
| 12/31/2019 | 1,039 | -595 | -344 | -327 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 314's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 314's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 314's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 314's revenue (16.6% per year) is forecast to grow faster than the Hong Kong market (7.3% per year).
High Growth Revenue: 314's revenue (16.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 314's Return on Equity is forecast to be low in 3 years time (4.4%).